PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

被引:251
作者
Oakervee, HE
Popat, R
Curry, N
Smith, P
Morris, C
Drake, M
Agrawal, S
Stec, J
Schenkein, D
Esseltine, DL
Cavenagh, JD [1 ]
机构
[1] St Bartholomews Hosp, Dept Haematol, London EC1A 7BE, England
[2] Belfast City Hosp, Belfast BT9 7AD, Antrim, North Ireland
[3] Millennium Pharmaceut Inc, Cambridge, MA USA
关键词
bortezomib; doxorubicin; dexamethasone; multiple myeloma;
D O I
10.1111/j.1365-2141.2005.05519.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bortezomib (formerly PS-341) has significant activity in patients with relapsed multiple myeloma (MM), its efficacy is increased with the addition of dexamethasone and it demonstrates synergy with doxorubicin, thus providing the rationale for combination therapy with bortezomib, doxorubicin and dexamethasone (PAD). Patients with untreated MM received four 21-d cycles of PAD, comprising bortezomib 1.3 mg/m(2) on days 1, 4, 8 and 11, along with dexamethasone 40 mg on days 1-4, 8-11 and 15-18 during cycle 1 and days 1-4 during cycles 2-4. During days 1-4, patients also received 0, 4.5 or 9 mg/m(2) of doxorubicin at dose levels 1, 2, and 3 respectively. Following peripheral blood stem cell (PBSC) collection, patients received high-dose melphalan (MEL200) with PBSC transplantation (PBSCT). After PAD induction alone, 20 of 21 patients (95%) achieved at least a partial response (PR), including complete response (CR) in five patients (24%). Twenty of 21 had PBSC mobilized, and 18 of 20 received MEL200/PBSCT. In an intention-to-treat analysis, response rates were: CR 43%, near CR 14%, very good PR 24%, PR 14% and stable disease 5%. PAD was effective, did not prejudice subsequent PBSC collection, and should be further evaluated in prospective randomized trials.
引用
收藏
页码:755 / 762
页数:8
相关论文
共 38 条
[1]  
Adams J, 1999, CANCER RES, V59, P2615
[2]   The proteasome: A suitable antineoplastic target [J].
Adams, J .
NATURE REVIEWS CANCER, 2004, 4 (05) :349-360
[3]   Graft outcome - Impact of complete remission with intensive therapy in patients with responsive multiple myeloma [J].
Alexanian, R ;
Weber, D ;
Giralt, S ;
Dimopoulos, M ;
Delasalle, K ;
Smith, T ;
Champlin, R .
BONE MARROW TRANSPLANTATION, 2001, 27 (10) :1037-1043
[4]   Single versus double autologous stem-cell transplantation for multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Facon, T ;
Guilhot, F ;
Doyen, C ;
Fuzibet, JG ;
Monconduit, M ;
Hulin, C ;
Caillot, D ;
Bouabdallah, R ;
Voillat, L ;
Sotto, JJ ;
Grosbois, B ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502
[5]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[6]   Treatment of multiple myeloma [J].
Barlogie, B ;
Shaughnessy, J ;
Tricot, G ;
Jacobson, J ;
Zangari, M ;
Anaissie, E ;
Walker, R ;
Crowley, J .
BLOOD, 2004, 103 (01) :20-32
[7]   Multiple myeloma [J].
Bataille, R ;
Harousseau, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (23) :1657-1664
[8]  
Berenson J, 2004, BLOOD, V104, p64A
[9]  
Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
[10]   Thalidomide in multiple myeloma: Current status and future prospects [J].
Cavenagh, JD ;
Oakervee, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) :18-26